Document:

EX-10.2

 Exhibit 10.2 

May 27, 2014 
 Mark Corrigan 

Dear Mark, 
 We are very pleased, in connection with the merger
between Epirus and Zalicus Inc. (to be renamed EPIRUS Biopharmaceuticals, Inc., for purposes herein, the “Company”) to offer you the position as Chairman of the Company’s Board of Directors (the “Board”). Your appointment is
based on the following terms and conditions: 
 Effective Date: Your appointment is subject to (i) closing of the merger and (ii) approval
by the Board (the later of these dates becomes the Effective Date). You will serve as Chairman of the Board commencing on the Effective Date until the annual meeting for the year in which your term expires or until your successor has been elected
and qualified, subject however, to your prior death, resignation, retirement, disqualification or removal from office. . 
 Board Compensation: You
will be eligible for a Retainer of $15,000 per in-person Board Meeting ($13,750 if telephonic). Compensation is based on the assumption there will be four (4) general board meetings per year, provided that your final per meeting
compensation will be paid quarterly and adjusted up or down if the number of actual meetings change, including final adjustment for Q4 based on your in-person attendance record during the year. 

Equity Compensation: Under our current equity plan (based on the current pre-merger capitalization), you will be granted an option to purchase
35,000 shares of the Company’s common stock annually starting at the first anniversary of your Effective Date and while you remain Chairman of the Board, the grant will vest quarterly over a one year period and with an exercise price
equal to the market value on your anniversary date. 
 Expenses: The Company will reimburse you for all reasonable travel (up to $12,000 per year)
and other related expenses incurred on behalf of the Company, upon submission by you of appropriate documentation of such expenses. 
 Please sign and
return to me one copy of this letter acknowledging your agreement to serve as Chairman of the Company’s Board under the terms set forth above. 
 Let
me know if you have any questions and we look forward to working with you. 
  

					
	Sincerely,	 		 	
			
	/s/ Amit Munshi	 		 	/s/ Mark Corrigan
			
	Amit Munshi	 		 	Mark CorriganEX-10.3

 Exhibit 10.3 

May 22, 2014 
 Bill Hunter 

Dear Bill, 
 We are very pleased to name you as one of our
director designees in connection with the merger between Epirus and Zalicus Inc. (to be renamed EPIRUS Biopharmaceuticals, Inc., for purposes herein, the “Company”). Your appointment to become a member of the Company’s Board of
Directors of the (the “Board”) is based on the following terms and conditions: 
 Effective Date: Your appointment is subject to
(i) closing of the merger and (ii) approval by the Board (the later of these dates becomes the Effective Date). You will serve as a member of the Board commencing on the Effective Date until the annual meeting for the year in which your
term expires or until your successor has been elected and qualified, subject however, to your prior death, resignation, retirement, disqualification or removal from office. Pending your official appointment, we will include your designation as one
of our director designees in the Company’s S4 Registration Statement being prepared for the merger approval. 
 Board Compensation: You will be
eligible for a Retainer of $8,750 per in-person Board Meeting ($7,500 if telephonic). Compensation is based on the assumption there will be four (4) general board meetings per year, provided that your final per meeting
compensation will be paid quarterly and adjusted up or down if the number of actual meetings change, including final adjustment for Q4 based on your in-person attendance record during the year. 

Equity Compensation: Under our current equity plan (based on the current pre-merger capitalization), you will be granted an option to purchase
100,000 shares of the Company’s common stock with an exercise price equal to the market value of the common stock as of the next Board meeting following merger closing. The grant will vest monthly over three years. Additionally, you will
be granted an option to purchase an additional 35,000 shares of the Company’s common stock annually starting at the first anniversary of your Effective Date and while you remain a Member of the Board, the grant will vest quarterly over a
one year period and with an exercise price equal to the market value on your anniversary date. 
 Committees: You have been asked to serve on the
Board’s Audit and Governance Committees, and that such committee assignment will be as agreed between you and the Company 
 Committee Compensation:
You will be eligible for an annual retainer of $5,000 to serve on the Audit Committee and an annual retainer of $2,500 to serve on the Governance Committee. 

Expenses: The Company will reimburse Director for all reasonable travel (up to $12,000 per year) and other related expenses incurred on behalf of the
Company, upon submission by Director of appropriate documentation of such expenses. 
 Please sign and return to me one copy of this letter acknowledging
your agreement to serve as a Director on the Company’s Board under the terms set forth above. 
 Let me know if you have any questions and we look
forward to working with you. 
 Sincerely, 
  

					
	 /s/ Amit Munshi
	 		 	 /s/ Bill Hunter

	Amit Munshi	 		 	Bill HunterEX-10.4

 Exhibit 10.4 

July 1, 2014 
 Julie McHugh 

Dear Julie, 
 We are very pleased to name you as one of our
director designees in connection with the merger between Epirus and Zalicus Inc. (to be renamed EPIRUS Biopharmaceuticals, Inc., for purposes herein, the “Company”). Your appointment to become a member of the Company’s Board of
Directors (the “Board”) is based on the following terms and conditions: 
 Effective Date: Your appointment is subject to (i) closing
of the merger and (ii) approval by the Board (the later of these dates becomes the Effective Date). You will serve as a member of the Board commencing on the Effective Date until the annual meeting for the year in which your term expires or
until your successor has been elected and qualified, subject however, to your prior death, resignation, retirement, disqualification or removal from office. 

Board Compensation: You will be eligible for a Retainer of $8,750 per in-person Board Meeting ($7,500 if telephonic). Compensation is based on
the assumption there will be four (4) general board meetings per year, provided that your final per meeting compensation will be paid quarterly and adjusted up or down if the number of actual meetings change, including final adjustment
for Q4 based on your in-person attendance record during the year. 
 Equity Compensation: Under our current equity plan (based on the current
pre-merger capitalization), you will be granted an option to purchase 100,000 shares of the Company’s common stock with an exercise price equal to the market value of the common stock as of the next Board meeting following merger
closing. The grant will vest monthly over three years. Additionally, you will be granted an option to purchase an additional 35,000 shares of the Company’s common stock annually starting at the first anniversary of your Effective Date
and while you remain a Member of the Board, the grant will vest quarterly over a one year period and with an exercise price equal to the market value on your anniversary date. 

Committees: You have been asked to serve on the Board’s Audit and Comp Committees, and that such committee assignment will be as agreed between
you and the Company 
 Committee Compensation: You will be eligible for an annual retainer of $5,000 to serve on the Audit Committee and an annual
retainer of $2,500 to serve on the Comp Committee. 
 Expenses: The Company will reimburse Director for all reasonable travel (up to $12,000 per
year) and other related expenses incurred on behalf of the Company, upon submission by Director of appropriate documentation of such expenses. 
 Please
sign and return to me one copy of this letter acknowledging your agreement to serve as a Director on the Company’s Board under the terms set forth above. 

Let me know if you have any questions and we look forward to working with you. 

Sincerely, 
  

					
	 /s/ Amit Munshi
	 		 	 /s/ Julie McHugh

	Amit Munshi	 		 	Julie McHughEX-10.5

 Exhibit 10.5 

EPIRUS Biopharmaceuticals, Inc. Non-Employee Director Compensation Policy 

Effective as of July 15, 2014 (the “Effective Date”), each member of the Board of Directors (the “Board”) who is not
also serving as an employee of EPIRUS Biopharmaceuticals (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation
Policy for his or her Board service. This policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board. 

Annual Cash Compensation 
 The annual retainers set forth
below assume that there are four in-person meetings per year; provided that no additional compensation will be paid if there are more than four in-person meetings in the applicable year. The per-meeting compensation (one-fourth of each annual
retainer) will be reduced by $5,000 if a telephonic meeting is held rather than an in-person meeting and there are less than four in-person meetings in such year. The retainers are paid quarterly in arrears and the retainer for the last quarter of
each year will be adjusted based on the Eligible Director’s in-person attendance during the year. 
  

	 	1.	Annual Board Service Retainer 

  

	 	a.	Chairman of the Board: $60,000 

  

	 	b.	All Eligible Directors other than the Chairman: $35,000 

  

	 	2.	Annual Committee Member Service Retainer 

  

	 	a.	Member of the Audit Committee: $5,000 

  

	 	b.	Member of the Compensation Committee: $2,500 

  

	 	c.	Member of the Corporate Governance and Nominating: $2,500 

  

	 	3.	Annual Committee Chair Service Retainer (in lieu of Committee Member Service Retainer) 

  

	 	a.	Chairman of the Audit Committee: $15,000 

  

	 	b.	Chairman of the Compensation Committee: $10,000 

  

	 	c.	Chairman of the Corporate Governance and Nominating Committee: $7,000 

 Each Eligible Director will also be
entitled to reimbursement in an amount of up to $12,000 per year for business expenses incurred on behalf of the Company, upon presentation of documentation acceptable to the Board. 

 Equity Compensation 

The equity compensation set forth below will be granted under the Company’s Amended and Restated 2004 Incentive Plan or its successor (the
“Plan”). All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the fair market value (as defined in the Plan) of the underlying common stock of the Company on the
date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan and the previously approved award agreement). 

 

	 	1.	Initial Grants: Each Eligible Director elected or appointed to the Board may receive a stock option at the time of initial election if, and in the amount, so determined by the Board. 

 

	 	2.	Annual Grant: On each anniversary of the Effective Date, each Eligible Director who continues to serve as an Eligible Director will be automatically, and without further action by the Board or the Compensation
Committee of the Board, granted a stock option for 4,641 shares pursuant to the form of award agreement previously presented to the Board. The annual grant will vest quarterly over a one-year period from the date of grant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]